Background: Infants and young children are particularly vulnerable to respiratory syncytial virus (RSV) infections, which may lead to acute bronchiolitis (AB), a serious illness of the lower respiratory tract. Interleukin-8 variations and other genetic variables may impact the severity of bronchiolitis, which varies greatly across people.
Aim: Focussing on its impact on illness susceptibility, severity, and clinical outcomes, this review seeks to thoroughly investigate the significance of the Interleukin-8 rs2227543 gene polymorphism in acute bronchiolitis. This study aims to assess the potential of interleukin-8 (IL-8) as a biomarker for illness progression and treatment response, as well as to investigate the association between IL-8 genetic variants and inflammatory responses in respiratory viral infections.
Conclusion: The findings of this research emphasise the importance of the IL-8 rs2227543 gene variant in the development of acute bronchiolitis in newborns from Egypt. IL-8 has promise as a diagnostic biomarker and a therapeutic target due to its role as a modulator of the inflammatory response. Personalised treatment options and the identification of high-risk newborns might be facilitated by a better understanding of genetic differences in IL-8. According to the available data, inflammatory regulation-related genetic variants may have a major role in determining the severity and prognosis of bronchiolitis. The therapeutic uses of IL-8 genetic testing in the management of acute bronchiolitis in paediatric populations need more investigation.